WE ARE ENDECE
ENDECE, LLC is a privately held biopharmaceutical company at the forefront of new drug discovery and development. Our library of proprietary compounds, invented and owned by ENDECE, was designed to stop disease by up-regulating specific biological pathways to stimulate a specific biological response. We focus on diseases whose treatment options are limited or non-existent and whose causes may not be well understood including Alzheimer’s disease, Neuropathic Pain and, demyelinating diseases such as, multiple sclerosis (MS), Transverse myelitis (TM) and osmotic demyelination syndrome (ODS) .
ENDECE was founded in 2006 and is located in Mequon, Wisconsin and San Francisco, California.
ENDECE will be attending Bio International Boston from June 4-7, 2018. In our meetings, we will be discussing ENDECE’s recent discovery that predicts NDC-1308 should demonstrate clinical efficacy for inducing remyelination in diseases such as MS, NMO and AD. ENDECE discovered NDC-1308 upregulates lipoprotein lipase (LPL) gene expression in addition to upregulating key genes for inducing OPC differentiation into mature, myelinating oligodendrocytes.read more
ENDECE, LLC announced that it is opening an office in San Francisco, establishing a West Coast presence that reinforces its commitment to advancing its pipeline of novel therapeutics for multiple sclerosis (MS), osmotic demyelination syndrome (ODS) and other neurodegenerative diseases.read more